Funding sources This study was supported by a grant from the British Skin Foundation (£1500).
Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study†
Article first published online: 13 JAN 2014
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 1, pages 150–156, January 2014
How to Cite
Darné, S., Leech, S.N. and Taylor, A.E.M. (2014), Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. British Journal of Dermatology, 170: 150–156. doi: 10.1111/bjd.12580
Conflict of interests None declared.
Plain language summary available online
- Issue published online: 13 JAN 2014
- Article first published online: 13 JAN 2014
- Accepted manuscript online: 12 AUG 2013 07:40AM EST
- Manuscript Accepted: 3 AUG 2013
- British Skin Foundation (£1500)
There is only retrospective evidence for the efficacy of narrowband ultraviolet B (NB-UVB) in children with eczema.
To measure the difference in means for objective scores [Six Area Six Sign Atopic Dermatitis score (SASSAD), percentage surface area] and quality-of-life scores, between patients treated with NB-UVB and unexposed cohorts at the end of treatment, and 3 and 6 months post-treatment.
Twenty-nine children aged 3–16 years for whom NB-UVB was indicated, were scored prospectively using SASSAD and percentage surface area involvement at baseline, at 12 weeks (end of treatment) and 3 and 6 months post-NB-UVB. Their scores were compared with those of unexposed children (n = 26) for whom NB-UVB phototherapy was indicated and offered, but who chose not to undertake treatment.
There was a 61% reduction in mean SASSAD score in the NB-UVB cohort compared with an increase of 6% in the unexposed cohort. Mean SASSAD score for the NB-UVB cohort at the end of treatment was 11·6 vs. 24·8 for the unexposed; difference in means −13·2 [95% confidence interval (CI) −18·7 to −7·7, P < 0·0001]. Mean surface area involvement at the end of treatment was 11% for the NB-UVB cohort vs. 36% for the unexposed cohort; difference in means −25% (95% CI −34% to −16%, P < 0·0001). Subjective and quality-of-life scores showed significant difference between cohorts at the end of treatment (P < 0·05). Objective scores remained significantly lower than in the unexposed cohort 3 and 6 months after treatment.
NB-UVB is clinically effective and improves quality of life in children with moderate-to-severe eczema. The effect is maintained for 6 months after treatment.